Triumeq can be coadministered with Norvir in the treatment of HIV. The drugs can be combined without any harmful interactions expected . Always consult with your physician before starting any treatment.
Triumeq belongs to a group of antiretroviral drugs used to treat HIV infection. The med reduces the viral load in the body while increasing the white blood cell count that helps fight infection. Dolutegravir, which is the main active ingredient of the drug, has the ability to inhibit the integrase of HIV, by binding to the active site of the integrase. After that, the stage of chain transfer is blocked during the integration of retroviral deoxyribonucleic acid. The latter process is necessary for the implementation of the HIV replication cycle . Other components of the drug, namely lamivudine, and abacavir, are potent selective HIV-1 and 2 reverse transcriptase inhibitors with an extended intracellular half-life.
Norvir (ritonavir) is an active inhibitor of HIV-1 and HIV-2 proteases. Studies have shown that Norvir is a potent inhibitor of the replication of both clinical and laboratory strains of HIV. This drug has high antiviral activity against strains of HIV obtained from patients from different countries and geographical areas. The drug can be used by children of 2 years of age and above, and adults for combination therapy. The degree of enhancement is related to the metabolism of the co-administered HIV protease inhibitor and the effect of the protease inhibitor on ritonavir metabolism .
Coadministration of ritonavir with dolutegravir/ lamivudine/ abacavir has not yet been properly studied. Ritonavir is not expected to significantly affect dolutegravir pharmacokinetics. After using cross-study assessments to pharmacokinetic data collected over a long period of time, dolutegravir does not affect the pharmacokinetics of ritonavir in any way. No interference is also expected with abacavir or lamivudine . It is still highly advised to consult a medical professional prior to administering these medicines together.